EZH2 can inhibit the transcription of tumor suppressor genes, and EZH2 overexpression or activation mutation is found in a variety of malignant tumors except melanoma, such as breast cancer, prostate cancer, uterine cancer, gastric cancer, and nuclear renal cell carcinoma. This evidence concerns the gene EZH2 and prostate carcinoma.